to Aug 10

2017 ALS Virtual Research Forum

A free, two-day, webinar featuring world-class researchers in the field of ALS

Wednesday, August 9 and Thursday, August 10, 2017
9 a.m. – 3 p.m. 

Hosted by: Dr. David Taylor
VP Research, ALS Canada

For a disease like ALS that has no cure and few effective treatments, research is a tremendous source of hope. For the second year running, the ALS Canada Research Program is presenting a free Virtual Research Forum open to anyone interested in learning more about some of the ALS research currently underway and therapies in development. Hosted by Dr. David Taylor, VP Research at ALS Canada, the Virtual Research Forum will feature more than twenty speakers and panelists and will take place over two days.

How to attend: All you need to participate is a computer with internet connection and audio capabilities via a telephone or computer. Advance registration is recommended because spots are limited. Please note that you must register separately for each day. You can attend as many or as few sessions as you like, and you can sign on and off as suits your schedule.

The Virtual Research Forum will be conducted in English, with two speakers – Bastien Paré from Laval University and Elsa Tremblay from l’Université de Montréal – who are able to take questions in French. We will be identifying future opportunities to offer research updates in both official languages. See below for an agenda to help you plan your attendance. As the agenda is finalized we will post updates on Facebook and Twitter to keep you up to date.

Register now for the Virtual Research Forum: Wednesday, August 9 and Thursday, August 10. For more information, please contact


Wednesday August 9
Register now

11:00 – 11:05 a.m.
Introduction by Dr. David Taylor: Welcoming Remarks
11:05 a.m. – 12:00 p.m.
*Dr. Michael Strong, Western University: ALS/FTD Overview
12:00 – 12:20 p.m.
*Dr. Lawrence Korngut, University of Calgary: Pimozide for the treatment of ALS
12:20 – 12:40 p.m.
* Dr. Mark Ware, McGill University: Cannabis study
12:40 – 1:00 p.m.
* Dr. Christen Shoesmith, London Health Sciences Centre: Canadian ALS Best Practice Recommendations
1:00 – 1:30 p.m.
AB Science, Pharmaceutical Company: Masitinib for the treatment of Amyotrophic Lateral Sclerosis (ALS) – Preclinical overview of clinical development
1:30 – 3:00 p.m.
Clinical Roundtable: Dr. Wendy Johnston (University of Alberta), Dr. Colleen O’Connell (Dalhousie University), Dr. Angela Genge (Montreal Neurological Institute), Dr. Christen Shoesmith (London Health Sciences Centre), etc.
3:00 – 3:30 p.m.
BrainStorm: NurOwn trials
3:30 – 4:00 p.m.
Cytokinetics, Biotechnology Company: Tirasemtiv trials
4:00 – 5:00 p.m.
Dr. Richard Bedlack, Duke Institute for Brain Sciences: Lazarus by Lunasin? Untangling an ALS X-file

Research projects marked with an asterisk (*) have been funded thanks to the generous support of donors across Canada and the provincial ALS societies.

Agenda: Thursday August 10
Register now

11:00 – 11:30 a.m.
Introduction by Dr. David Taylor: Ice Bucketiology
11:30 – 11:50 a.m.
*Bastien Paré, Université Laval: ALS skin
11:50 a.m. – 12:10 p.m.
*Dr. Martin Duennwald, Western University: ALS yeast
12:10 – 12:30 p.m.
*Dr. Carl Laflamme, McGill University: Toward enhanced understanding of the function C9ORF72/SMCR8 in autophagy
12:30 – 12:50 p.m.
Dr. Phil McGoldrick, University of Toronto: C9 work/nucleocytoplasmic trafficking
12:50 – 2:20 p.m.
Preclinical Roundtable: Dr. Ian Mackenzie (University of British Columbia), Dr. Christine Vande Velde (Université de Montréal) etc.
2:20 – 2:40 p.m.
Dr. Neil Cashman, University of British Columbia: Protein misfolding in ALS
2:40 – 3:00 p.m.
Dr. Matthew Miller, McMaster University: Viral response mechanisms
3:00 – 3:20 p.m.
*Elsa Tremblay, Université de Montréal: Neuromuscular junction
3:20 – 3:40 p.m.
*Dr. Kelvin Jones, University of Alberta: Exercise study ALS
3:40 – 4:50 p.m.
4:50 – 5:00 p.m.
Dr. David Taylor: Wrap-Up

Research projects marked with an asterisk (*) have been funded thanks to the generous support of donors across Canada and the provincial ALS societies.

View Event →

Webinar: Canada Research Program

Thursday, July 20, 2017
10 a.m. – 45 minutes + questions

Hosted by: Dr. David Taylor
VP Research at ALS Canada

The provincial ALS Societies have been funding important ALS research for over thirty years. This webinar will discuss the history of Canada’s research funding through to the current program, which has grown substantially in recent years. There is currently more research to be done than funding available, so the webinar will also explain Canada’s approach to research funding, which is focused on maximizing the impact of donor dollars by awarding grants to projects believed to offer the most promise to advance the field of ALS research.

Register for the Webinar

View Event →

Webinar: Canadian ALS Research

Tuesday, July 11, 2017
10 a.m. 45 minutes + questions

Hosted by: Dr. David Taylor
VP Research at ALS Canada

In Canada, we are privileged to have an exceptional ALS research community that is actively contributing to advancing the global field of ALS research. This webinar will provide an overview of the Canadian ALS research community and highlight examples of ALS researchers and projects that contribute to the high-quality research being done in Canada. Much of this important Canadian ALS research would not be possible without the generous support of donors.

Register for the Webinar

View Event →

The Canadian ALS Neuroimaging Consortium (CALSNIC) Webinar

Hosted by: Dr. Sanjay Kalra

Co-Director Edmonton ALS Clinic at University of Alberta
Professor, Division of Neurology, Department of Medicine
Principal Investigator, Canadian ALS Neuroimaging Consortium
Adjunct Professor, Department of Computing Science
Adjunct Professor, Department of Biomedical Engineering

Dr. Kalra is a world expert on using advanced brain imaging techniques to better understand ALS. His work is primarily focused on the potential to find a biomarker that would allow physicians to detect the disease earlier, monitor disease progression and evaluate new therapies. Such a tool would likely both accelerate treatment testing and make new treatments more effective by providing a means of earlier intervention. In recent years, Dr. Kalra has collaborated with ALS clinicians across the country to develop a standardized Canadian platform of high powered brain imaging through a consortium called The Canadian ALS Neuroimaging Consortium (CALSNIC). Setting up this cross-Canada imaging network is funded through the largest ever grant provided by the ALS Canada Research Program, as a successfully peer reviewed application to the ALS Canada-Brain Canada Arthur J Hudson Translational Team Grant competition in 2015. This webinar will introduce CALSNIC, the researchers involved and demonstrate many of the fascinating techniques used to look for imaging biomarkers. An opportunity to ask Dr. Kalra questions will be available after the webinar.

View Event →